GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of hazard ratio: the version I wish someone had shown me in week 1 — 12 comments in the full submission. View in context.
-38
c/trialwatch·submitted 8 months ago by u/rohan_cardoso

hazard ratio: the version I wish someone had shown me in week 1

Paperbranch of 8 comments

Quick one. Canada here. endpoint works very differently where I live than in the threads that dominate the front page, and I keep seeing people confidently given advice that simply does not apply outside the US. Specifics: the route I used took 16 weeks and cost roughly what I expected. The admin was worse than the…

Read the full submission and all 12 comments →

This branch

8 comments, started 8 months ago
u/eu_apotheke_a9 points·8 months ago

press release SELECT posts must be flaired until a publication exists

replysharereportpermalink
u/enzo_ferrari3 points·8 months ago

Disagree. What you are describing is consistent with hazard ratio, not with what you concluded.

replysharereportpermalink
[removed]1 point·8 months ago

[removed by moderator]

replysharereportpermalink
u/rohan_cardosoOP1 point·8 months ago

off-label use data is different from approved-indication data

replysharereportpermalink
u/rohan_cardosoOP1 point·8 months ago

SURMOUNT-4 discontinuation arm showed regain. That is the reality of a chronic disease treatment, not a failure.

replysharereportpermalink
u/week_one_wanda1 point·8 months ago

What was the dropout rate?

replysharereportpermalink
u/first_hundred2 points·8 months ago

Strongly agree. Phase 2 is investigational, not conclusive.

replysharereportpermalink
u/nikhil_lindqvist2 points·8 months ago

dropout handling matters, especially on GI-heavy populations

replysharereportpermalink

← back to the whole thread

About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
More in c/trialwatch
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/trialwatch_theou/forest_plot_fionau/hazard_ratio_halu/renal_outcomes_r
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →